In:
Annals of the New York Academy of Sciences, Wiley, Vol. 1139, No. 1 ( 2008-10), p. 63-69
Abstract:
A recent study showed a significant association between schizophrenia in European samples and the glutamate cysteine ligase modifier (GCLM) subunit gene, which is the key glutathione (GSH)‐synthesizing enzyme. Since the symptoms of methamphetamine (METH)‐induced psychosis are similar to those of schizophrenia, the GCLM gene is thought to be a good candidate gene for METH‐use disorder or related disorders. To evaluate the association between the GCLM gene and METH‐use disorder and schizophrenia, we conducted a case‐control study of Japanese subjects (METH‐use disorder, 185 cases; schizophrenia, 742 cases; and controls, 819). Four SNPs (2 SNPs from an original report and JSNP database, and 2 “tagging SNPs” from HapMap database) in the GCLM gene were examined in this association analysis; one SNP showed an association with both METH‐use disorder and METH‐induced psychosis. After Bonferroni's correction for multiple testing, however, this significance disappeared. No significant association was found with schizophrenia. Our findings suggest that a common genetic variation in the GCLM gene might not contribute to the risk of METH‐use disorder and schizophrenia in the Japanese population.
Type of Medium:
Online Resource
ISSN:
0077-8923
,
1749-6632
DOI:
10.1196/nyas.2008.1139.issue-1
DOI:
10.1196/annals.1432.022
Language:
English
Publisher:
Wiley
Publication Date:
2008
detail.hit.zdb_id:
2834079-6
detail.hit.zdb_id:
211003-9
detail.hit.zdb_id:
2071584-5
SSG:
11
Permalink